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I refer to a previous Letter to the Editor and its reply [1] regarding
the excellent meta-analysis on ferroportin disease performed by
Mayr et al. in the Journal of Hepatology in November 2010 [2].
The SLC40A1-R178Gmutation is discussed and whether it is a dis-
ease-causing mutation with incomplete penetrance or a poly-
morphism. Upon further inspection of the original report by
Speletas et al., describing the R178G mutation in a Greek family,
published in the journal Blood Cell Molecules and Diseases in 2008
[3], I have come to the conclusion that an error was made in the
designation of this mutation. Rather than an arginine to glycine
substitution at position 178 (R178G), the mutation is in fact an
arginine to glutamine substitution (R178Q). In the text of this
report [3], the mutation is referred to as a guanine to adenine
substitution at position 963 of the NCBI reference sequence
NM_014585 (963G>A). This reference sequence has been updated
ﬁve times and the numbering appears to refer to NM_014585.3
(updated 17 Nov 2006), the current sequence is NM_014585.5
(updated 12 Jan 2013). After converting this numbering to the
cDNA sequence, using the ﬁrst base of the open reading frame
as the beginning of the sequence, the mutation becomes
c.533G>A. The authors also include a sequence chromatogram
in Fig. 2, clearly showing a heterozygous C to T change on the
reverse strand of the sequence that corresponds to the
c.533G>A change. The error appears to have come from the con-
version of this nucleotide substitution to the amino acid change.
The R178 codon is CGA and the c.533G>A substitution changes it
to CAA, which codes for glutamine and not for glycine. The error
may have occurred due to confusion in the single letter nomen-
clature for amino acids, G for glycine and Q for glutamine. This
error has ﬂowed through to a number of other publications
including the Mayr et al. meta-analysis and indeed one of my
own [4]. In the Mayr et al. meta-analysis the R178G mutation is
wrongly referred to in Table 3 as the nucleotide change
c.532C>A, clearly different from that reported by Speletas et al.
and would lead to a codon change from CGA to AGA, which is
in fact silent, both codons coding for arginine. Upon further anal-
ysis of Table 3 from the Mayr et al. meta-analysis, there are still a
number of mistakes in the nucleotide numbering of mutations,
even after mistakes in the reference column were corrected in a
Corrigendum published in September 2011.
Moreover, in the original Speletas et al. publication, the
c.533G>A mutation is claimed to be a novel mutation, however,
in a publication by Cunat et al. from 2007, the same c.533G>A
(R178Q) mutation is reported in a 70-year old female with
hyperferritinaemia [5]. Having said this, the Cunat et al. publica-
tion was published online after the Speletas et al. paper was
accepted for publication, so the mutation would have been novel
at the time. The ethnic origin of the Cunat et al. patient is notJournal of Hepatology 20given, although it appears that all patients analysed in this study
were recruited from centres in France. Cunat et al., also screened
100 control chromosomes and the c.533G>A mutation was
absent in this control group. In the Speletas et al. Letter to the Edi-
tor [1], the authors provide an update on the family previously
described with the mutation that should now be referred to as
R178Q, and also show that the mutation is not present in a con-
trol group comprising 253 bone marrow donors from central
Greece. This, combined with the Cunat et al. report, provides fur-
ther support that R178Q is indeed a rare mutation that causes the
classical phenotype of ferroportin disease in two isolated fami-
lies, with incomplete penetrance in members of the Greek family.
Speletas et al. also describe a PCR-RFLP method for detecting the
‘‘R178G’’ mutation and state that this method can also be used to
detect another mutation found at the 178R amino acid position
[1]. Presumably, they were referring to the R178Q mutation
described by Cunat et al., unwittingly not realising that these
are in fact the same mutation.
The incorrect designation of the SLC40A1-R178Qmutation and
subsequent ﬂow on into other publications has led to some confu-
sion. I think it is worth highlighting that vigilance and veriﬁcation
during the initial sequence analysis stage and use of standard
nomenclatures for mutations may help avoid and perpetuate
these errors in the future. The use of the cDNA numbering posi-
tion, starting from the ﬁrst base of the open reading frame (e.g.,
c.533G>A), rather than nucleotide positions obtained from NCBI
reference sequences that are regularly updated, would help stan-
dardize nucleotide mutation nomenclature. Vigilance in conver-
sions between amino acid names, three letter and single letter
codes is also important when reporting protein sequence changes.13 vol. 59 j 396–401
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Reply to: ‘‘SLC40A1-R178G or R178Q and ferroportin disease? A call
for vigilance in mutation reporting’’
To the Editor:
We appreciate the observation by Dr. Wallace uncovering our
error in citing unwittingly the nomenclature of amino acid alter-
ation of the mutation g.963G>A (according to the NCBI reference
sequence NM_014585) of SLC40A1 gene, as R178G (Arg178Gly)
instead of R178Q (Arg178Gln). An Erratum has already been sub-
mitted in concern to our initial publication [1]. We have to
emphasize that all the data presented in both our initial publica-
tion describing this alteration and in the Letter to the Editor [2]
are absolutely correct. At the time of the submission of the initial
publication in Blood Cells Molecules and Diseases, this alteration
(R178Q) was really novel, as the paper of Cunat et al. [3] had not
appeared in the literature. Unfortunately, a database of ferropor-
tin gene (SLC40A1) mutations is not yet available. It would be
worthy such a database to be established for SLC40A1, as it is
the rule for other genes of clinical interest. Very usefully, a formal
and detailed review of the incoming alterations is provided by
such databases.
To the end, we have recently performed a detailed bioinfor-
matic analysis in order to assess whether this alteration is likely
to be deleterious and, if possible, to determine which aspects of
protein function are affected. For this purpose, we used two dif-
ferent software packages, namely SIFT (Sorting Intolerant From
Tolerant; available at: http://sift.bii.a-star.edu.sg/) and PolyPhen2
(available at: http://genetics.bwh.harvard.edu.pph2/) and we
determined that the R178Q mutation is rather deleterious for
protein function (intolerant on SIFT analysis with a probability
score 0.00, and probably damaging on PolyPhen2 analysis: sensi-
tivity score 0.00, speciﬁcity score: 1.00), causing the emergence
of the classical ferroportin disease.
We honestly apologize for our mistake. Such mistakes would
be really avoided using the cDNA numbering position rather than
nucleotide positions obtained from NCBI reference sequences
(that are regularly updated) and the presentation of amino acid
substitutions by both three letter and single letter codes, as it is
rightly proposed by Dr. Wallace.
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